• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Erasca Inc.

    4/28/26 4:42:42 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ERAS alert in real time by email
    DEFA14A 1 d946335ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Erasca, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


     

     

    LOGO

    P.O. BOX 8016, CARY, NC 27512-9903

     

     

    LOGO

       LOGO

     

     

     

     

    Erasca, Inc.

     

    Annual Meeting of Stockholders

     

    Friday, June 26, 2026 11:30 AM, Pacific Time

     

    Annual Meeting to be held live via the internet - please visit www.proxydocs.com/ERAS for more details

     

    You must register to attend the meeting online and/or participate at www.proxydocs.com/ERAS

     

     

    For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/ERAS

     

    To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

     

    If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 15, 2026.

     

     

    SEE REVERSE FOR FULL AGENDA

      

     

    LOGO

     

     

     

     

     

    Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K

     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 26, 2026 For Stockholders of record as of April 27, 2026

     

    To order paper materials, use one of the following methods.

     

    LOGO

    Internet:

    www.investorelections.com/ERAS

     

      LOGO

    Call:

    1-866-648-8133

     

      LOGO

    Email:

    paper@investorelections.com

     

    * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

     

    LOGO

    Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

    Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO

     

    Erasca, Inc. Annual Meeting of Stockholders

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

       FOR ON PROPOSALS 1 AND 2

     

     

      

     

    PROPOSAL

     

    1. 

      

    To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified

      

     

    1.01 Alexander W. Casdin

      

    1.02 Julie Hambleton, M.D.

      

    1.03 Michael D. Varney, Ph.D.

    2.

      

    To ratify the appointment of KPMG LLP as our indpendent registered public accounting firm for the fiscal year ending December 31, 2026

    3.

      

    To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting

    Get the next $ERAS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ERAS

    DatePrice TargetRatingAnalyst
    1/27/2026$16.00Outperform
    Mizuho
    1/7/2026$5.00Overweight
    Piper Sandler
    10/16/2025$4.00Buy
    Stifel
    9/3/2025Buy → Underperform
    BofA Securities
    8/18/2025$2.00Overweight → Equal-Weight
    Morgan Stanley
    3/26/2025$5.00Outperform
    Raymond James
    11/18/2024$6.00Buy
    Jefferies
    3/11/2024$8.00Overweight
    CapitalOne
    More analyst ratings

    $ERAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Casdin Alexander W. bought $181,920 worth of shares (80,000 units at $2.27) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    5/22/24 6:57:45 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Start Valerie Denise Harding bought $18,480 worth of shares (10,000 units at $1.85) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    12/8/23 9:10:12 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lim Jonathan E bought $1,696,179 worth of shares (1,000,000 units at $1.70) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    12/6/23 7:41:47 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Erasca Inc.

    SCHEDULE 13G/A - Erasca, Inc. (0001761918) (Subject)

    5/15/26 4:34:32 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Erasca Inc.

    SCHEDULE 13G/A - Erasca, Inc. (0001761918) (Subject)

    5/15/26 10:06:32 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Erasca Inc.

    SCHEDULE 13G - Erasca, Inc. (0001761918) (Subject)

    5/15/26 8:20:31 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho resumed coverage on Erasca with a new price target

    Mizuho resumed coverage of Erasca with a rating of Outperform and set a new price target of $16.00

    1/27/26 8:45:40 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Erasca with a new price target

    Piper Sandler initiated coverage of Erasca with a rating of Overweight and set a new price target of $5.00

    1/7/26 9:10:17 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Erasca with a new price target

    Stifel initiated coverage of Erasca with a rating of Buy and set a new price target of $4.00

    10/16/25 8:25:25 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Garner Ebun

    4 - Erasca, Inc. (0001761918) (Issuer)

    4/3/26 9:00:03 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Morris Shannon exercised 20,000 shares at a strike of $1.70 and sold $300,760 worth of shares (20,000 units at $15.04) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    3/6/26 9:00:03 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman & CEO Lim Jonathan E

    4 - Erasca, Inc. (0001761918) (Issuer)

    1/30/26 9:05:03 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Erasca to Present at the Jefferies Global Healthcare Conference

    SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY. Management will participate in a fireside chat on Wednesday, June 3, 2026, at 3:10 pm Eastern Time and will also participate in one-on-one investor meetings. A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcas

    5/27/26 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Reports First Quarter 2026 Business Updates and Financial Results

    Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents ERAS-0015 monotherapy expansion and combination dose escalation data expected in H1 2027; ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $409 million as of March 31, 2026 expected to fund operations into H2 2028 SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, an

    5/11/26 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

    SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Merck, known as MSD outside of the United States and Canada. This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of patients with RAS-mutant (RASm) solid tumors. Erasca is sponsoring the study, and Merck is supplyi

    5/11/26 7:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Leadership Updates

    Live Leadership Updates

    View All

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Erasca Appoints Jean Liu to its Board of Directors

    SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

    4/27/22 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Strengthens Leadership Team with Two Key Executive Appointments

    Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

    1/18/22 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Financials

    Live finance-specific insights

    View All

    Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

    Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% uORR at 16-32 mg QD PAD, 42% uORR at 24-32 mg QD RDE, and 50% uORR at 32 mg QD Monotherapy generally well-tolerated with mostly low-grade AEs, no DLTs as of DCO, and low rate of dose reductions and no discontinuations due to TRAEs Preliminary data suggest ERAS-0015 may combine safely with standard-of-care doses of panitumumab with no DLTs as of DCO (N=3) and 1/1 uPR in CRC Well-behaved PK, with dose-dependent increase in PK exposure up to MAD of 40 mg QD and no exposure plate

    4/27/26 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

    SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss preliminary Phase 1 dose escalation data for its potentially best-in-class pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors today, Monday, April 27, 2026, at 4:30 pm ET. Conference Call and Webcast InformationErasca will hold a conference call and webcast Monday, April 27, 2026, at 4:30 pm ET. The webcast link for the conference call is her

    4/27/26 8:30:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

    Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

    5/16/24 8:02:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 5:13:04 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 4:04:32 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Erasca Inc.

    SC 13G - Erasca, Inc. (0001761918) (Subject)

    11/14/24 1:28:34 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care